The Recovery Curriculum - 201b

Medication, Stigma, and Recovery

The Recovery Curriculum — Article 3

This is the third piece in the Recovery Curriculum, a seven-part series on how recovery works and who it’s actually built for. Article 1 examined equity, access, and who the system is built for. Article 2 mapped how treatment actually works. This is the 201 level continued: medication, what it does, and why the stigma around it costs lives. Fair warning, this is a longer article, but worth your time!

A note on language.

The term “medication-assisted treatment” (MAT) carries a lot of weight and is worth explaining before we go further. MAT is a broader framework of pharmacologically-based treatment covering both opioid use disorder and alcohol use disorder, combining medication with counseling and support services. MOUD — medications for opioid use disorder — is the more precise term referring specifically to medications used to treat OUD, and it’s the terminology now preferred by SAMHSA and NIDA.

The shift happened for a few reasons. Clinically, MOUD is more accurate because it reflects the OUD-specific scope rather than the broader MAT umbrella. It’s also a response to stigma: “assisted” implies the medication is a supplement to whatever real treatment is happening somewhere else, rather than a primary treatment in its own right. That framing has consequences for how patients understand their own care and how communities receive them.

In practice, you’ll hear both terms used interchangeably and distinctly depending on the setting and who’s in the room. People not directly involved with these resources often have a foggy concept of what MAT and MOUD actually are and what they do. That’s part of why this article exists.

This piece uses MAT because it’s the term most readers will recognize. But the distinction is worth knowing.

MAT: What it is and isn’t.

Medication-assisted treatment is the use of FDA-approved medications combined with counseling and behavioral support to treat substance use disorders, primarily opioid use disorder. The three medications most commonly used are methadone, buprenorphine (often known by the brand name Suboxone, which combines buprenorphine with naloxone), and naltrexone (known by the brand name Vivitrol).

To understand how they work, it helps to understand what opioids do to the brain in the first place.

The brain has a network of opioid receptors, part of the natural system that regulates pain, stress, pleasure, and reward. The body produces its own substances that activate them. Endorphins are the most familiar example. Opioid drugs work by flooding those receptors with something far more powerful than what the brain makes on its own. The effect is intense, and over time the brain adapts. It begins producing less of its own activating substances and becomes reliant on the external opioid just to feel normal. Not high. Normal. That is the neurological reality of opioid use disorder. Withdrawal is what happens when the external supply disappears and the brain’s own system can’t compensate fast enough.

MAT medications work within that same receptor system, but in controlled, predictable ways.

Methadone is a full agonist, meaning it binds to opioid receptors and activates them fully, doing the job the brain has become dependent on but slowly and steadily rather than in a spike. No rush, no high when taken as prescribed, just stable function. It has been used to treat opioid use disorder since the 1960s. Buprenorphine is a partial agonist. It binds to and activates the receptors, but only partially, with a ceiling effect that limits misuse potential while still preventing withdrawal and craving. Because the receptors are occupied and activated, there’s significantly less effect if someone uses opioids on top of it. Naltrexone is an antagonist. It binds to opioid receptors without activating them at all, simply occupying the space. If opioids arrive, there’s nowhere for them to connect and no effect is produced. It has no opioid activity of its own and is also FDA-approved for alcohol use disorder.

One critical clinical distinction: naltrexone is not for withdrawal management. Someone must be fully opioid-free before starting it, typically for at least several days depending on the opioid involved, because starting too soon precipitates immediate and severe withdrawal. This makes naltrexone a different clinical tool than methadone or buprenorphine, suited for people who have already cleared opioids from their system and want a non-opioid option for relapse prevention.

These medications are not interchangeable, and they are not equivalent in their evidence base. Methadone and buprenorphine have decades of research behind them. People with opioid use disorder taking prescribed methadone or buprenorphine are 50% less likely to die of overdose compared to no treatment. Naltrexone’s evidence base for OUD is thinner, and some research suggests it may actually increase overdose risk if someone returns to use after the blocking effect wears off, because tolerance drops while the expectation of use doesn’t.

That distinction matters clinically. It also rarely gets explained to patients.

What the evidence says.

The evidence for MAT, particularly methadone and buprenorphine, is decades old, replicated across populations and settings, and consistent. This is not new science.

A Yale-led study published in 2024 compared overdose death rates across different treatment approaches. People on methadone had a 38% lower risk of fatal overdose than people receiving no treatment at all. People on buprenorphine had a 34% lower risk. People in abstinence-based treatment with no medication had a 27% to 77% higher risk of fatal overdose than people receiving no treatment whatsoever.

That range deserves an explanation. The mechanism isn’t that abstinence-based treatment is harmful in itself. Tolerance is the culprit. When someone stops using opioids through an abstinence-based program, their tolerance tends to drop. If they return to use, and many do, their body can no longer handle the dose it once could. In the era of fentanyl, that tolerance window is lethal. Medication-based treatment keeps tolerance stable, which is part of why it keeps people alive even when they aren’t maintaining perfect abstinence.

Research consistently shows that patients on MAT are significantly more likely to remain in treatment compared to those in abstinence-only programs. Retention is one of the strongest predictors of recovery outcomes we have. Anything that keeps people engaged matters.

Getting to it.

Knowing that medication works and being able to access it are two different things. For many people, the gap between the two is where recovery ends before it starts.

Start with geography. Methadone for opioid use disorder cannot be prescribed at a standard clinic or doctor’s office. It can only be dispensed through federally certified Opioid Treatment Programs. In early treatment, patients typically have to show up in person every single day to receive their dose. In a city, that’s inconvenient. In a rural county with one clinic two hours away, it means choosing between treatment and employment, between treatment and childcare, between treatment and the practical reality of a life that doesn’t stop because you’re in recovery. Many people make the only calculation available to them and go without.

Buprenorphine is more accessible. It can be prescribed in office-based settings, which means a primary care provider or a psychiatrist with the right certification can prescribe it. But that certification matters, and not every provider has pursued it. Only about 4% of providers nationally offer all three FDA-approved medications. Most offer one, if any. In rural areas, the provider who has any MAT capacity at all may have a months-long waitlist. The medication that could keep someone alive is theoretically available. Getting to it is a different story.

Then there is insurance. Medicaid covers MAT, but coverage doesn’t mean access. Prior authorization requirements, step therapy protocols that require failing one medication before accessing another, and the administrative burden placed on providers to justify treatment to MCOs add friction to a process that needs to be as frictionless as possible. Someone in acute need of stabilization does not have weeks to spend navigating an insurance appeal.

And then there is the criminal justice system. Drug courts were designed to divert people from incarceration into treatment. In practice, many of them bar MAT as a condition of participation. A judge with no medical training can require someone to stop a medication that is keeping them alive, and call it recovery. Jails and prisons across the country do the same. The STAT investigation found this pattern operating at scale, people cycling through criminal justice settings, losing access to medication, and dying of overdose shortly after release when tolerance is low and the fentanyl supply is not.

This is what it looks like when recovery is built around what’s administratively convenient rather than what works. The medication exists. The evidence is not in question. What stands between a person and the treatment that could save their life is distance, paperwork, provider availability, insurance bureaucracy, and in some cases a courtroom. That is a design problem, not a personal failing.

The stigma problem.

Here is where it gets complicated.

The external stigma around MAT is real and well-documented. Drug courts, jails, probation programs, and sober living homes across the country have policies, formal and informal, that require people to stop MAT as a condition of participation. A STAT investigation published throughout 2024 found that thousands of institutions claiming to offer refuge from opioid addiction are among those most hostile to lifesaving addiction medications, describing a culture that ignores medical consensus and silences dissent.

There is also stigma operating inside recovery communities, and that is a harder conversation.

Despite MAT’s proven effectiveness, resistance within 12-step communities, often reinforced by old-school sponsors or group norms, places patients at risk. The belief that medication means you aren’t really sober is not fringe. It is common, and costs lives.

NA’s official 2024 literature is actually more open than many meetings may reflect. It reaffirms that the only requirement for membership is “a desire to stop using,” not abstinence from medication. The gap between what the literature says and what happens in practice is where people get hurt.

This article is not an indictment of 12-step recovery. Twelve-step programs have saved lives for nearly a century. The point is narrower: the idea that medication disqualifies someone from real recovery is not supported by evidence, is not the official position of these organizations, and is actively dangerous in the era of fentanyl.

What this means in practice.

For clinicians: MAT should be presented as a first-line treatment option for opioid use disorder, not a last resort or a consolation prize. The conversation with clients about medication should happen early, should be honest about what the evidence shows, and should not be shaped by the clinician’s own discomfort with the idea.

For people in or considering recovery: you are not less recovered because you take medication. You are not cheating. You are treating a medical condition with medicine that works. What you do with the stability that medication provides, the therapy, the community, the rebuilding, is still entirely yours.

For everyone: the goal is people staying alive. A recovery that requires choosing between medication and belonging is a recovery framework that will lose people it could have kept.

Knowing how it works doesn’t fix any of that. But it makes it harder for the stigma to pass itself off as principle.

Sources: Overdose death risk data draws on Heimer et al. (2024), “Receipt of Opioid Use Disorder Treatments Prior to Fatal Overdoses,” American Journal of Public Health, and supporting data cited by the National Association of Counties (NACo). The 50% overdose reduction figure for methadone and buprenorphine is drawn from NACo’s MAT policy brief citing multiple peer-reviewed studies. Treatment retention data draws on controlled trials and systematic reviews summarized in Fischer et al. (2017), Canadian Family Physician, and Degenhardt et al. (2023), The Lancet Psychiatry. The 4% provider figure is drawn from Pew Trusts data cited by BHG Recovery (bhgrecovery.com, 2025). The STAT “War on Recovery” investigation (Lev Facher, 2024) informs the access and external stigma sections and is available at statnews.com. The 2025 peer-reviewed paper “Shattering the STIGMA: Talking Openly About MAT in 12-Step Recovery Programs” (Klein, Franco, Scioli), published in the Journal of Substance Abuse Treatment, informs the internal stigma section. NA’s 2024 resource on MOUD is publicly available at na.org. MAT and MOUD terminology draws on SAMHSA guidance and BHG Recovery’s MAT vs. MOUD overview (bhgrecovery.com, 2025).